3679.ppt
TRANSCRIPT
![Page 1: 3679.ppt](https://reader035.vdocuments.site/reader035/viewer/2022062802/563dbb99550346aa9aae91ef/html5/thumbnails/1.jpg)
Diabetic Neuropathy
Peter Lapinskas
www.lapinskas.com
![Page 2: 3679.ppt](https://reader035.vdocuments.site/reader035/viewer/2022062802/563dbb99550346aa9aae91ef/html5/thumbnails/2.jpg)
Control of blood sugar
Sugar (glucose) required for metabolism and energyProduced from digestion and breakdown of starchesBlood glucose concentration controlled by insulinInsulin made in β-cells in Islets of Langerhans in the
pancreasInsulin controls transfer of glucose from blood into
many cells
![Page 3: 3679.ppt](https://reader035.vdocuments.site/reader035/viewer/2022062802/563dbb99550346aa9aae91ef/html5/thumbnails/3.jpg)
Diabetes Mellitus
Defect in the glucose control systemType 1 diabetes
‘Juvenile onset diabetes’‘Insulin dependent diabetes (IDDM)’Reduced insulin production Caused by autoimmune destruction of
insulin-producing cellsTreated with insulin replacement
![Page 4: 3679.ppt](https://reader035.vdocuments.site/reader035/viewer/2022062802/563dbb99550346aa9aae91ef/html5/thumbnails/4.jpg)
Diabetes Mellitus
Type 2 diabetes‘Late onset diabetes’‘Non-insulin dependent diabetes (NIDDM)’Reduced sensitivity to insulinAssociated with obesity, physical inactivity,
poor diet, genetic predispositionMay eventually become IDDM
![Page 5: 3679.ppt](https://reader035.vdocuments.site/reader035/viewer/2022062802/563dbb99550346aa9aae91ef/html5/thumbnails/5.jpg)
Diabetes Mellitus
Drug categories for type 2 diabetesInsulin secretagogues
Enhance insulin secretion (eg Sulphonylurea)
Insulin sensitisersEnhance muscle cell sensitivity (PPARg agonists) Slow down glucose release from liver (Biguanides)
Digestion modulatorsHinder starch digestion (α-glucosidase inhibitors)Block fat absorption to reduce obesity (Orlistat)
![Page 6: 3679.ppt](https://reader035.vdocuments.site/reader035/viewer/2022062802/563dbb99550346aa9aae91ef/html5/thumbnails/6.jpg)
Long-term problems (1)
Microvascular damageNephropathy (kidneys)
Damage to glomeruliBlood albumin leaks into urine (diagnostic)Loss of filtration capacity (kidney failure)
Retinopathy (eyes)Proliferation of fragile blood vessels in retinaBlood protein leaks into eyeScar tissue damages retina
Neuropathy (nerves)
![Page 7: 3679.ppt](https://reader035.vdocuments.site/reader035/viewer/2022062802/563dbb99550346aa9aae91ef/html5/thumbnails/7.jpg)
Long-term problems (2)
Macrovascular damageAtherosclerosis (deposits in blood vessels)
75% of early diabetic deaths
Angina (reduced blood flow to heart)Chest pains
Hypertension (high blood pressure)Heart and kidney disease
‘Diabetes - a leading cause of death in USA’
![Page 8: 3679.ppt](https://reader035.vdocuments.site/reader035/viewer/2022062802/563dbb99550346aa9aae91ef/html5/thumbnails/8.jpg)
Diabetic Neuropathy
Damage to nerve fibres and capillariesSymptoms depend on nerves involved
Motor fibres → Muscular weaknessSensory fibres → Loss of sensation
also prickling, tingling, aching and pain
Autonomic fibres → loss of functionfunctions not under conscious control such as
digestion, bladder, genitals, cardiovascular.
![Page 9: 3679.ppt](https://reader035.vdocuments.site/reader035/viewer/2022062802/563dbb99550346aa9aae91ef/html5/thumbnails/9.jpg)
Diabetic Neuropathy
Other ConsequencesDiabetic foot (15% of all diabetics)Compression neuropathies
eg carpal tunnel syndrome
Risk factorsSmoking, >40 years old, poor glucose controlAffects Type 1 and Type 2
![Page 10: 3679.ppt](https://reader035.vdocuments.site/reader035/viewer/2022062802/563dbb99550346aa9aae91ef/html5/thumbnails/10.jpg)
Incidence of Diabetic Neuropathyas a proportion of all diabetics 20 years after diagnosis
No neuropathy 10%
Asymptomatic 40%
Symptomatic 50%
![Page 11: 3679.ppt](https://reader035.vdocuments.site/reader035/viewer/2022062802/563dbb99550346aa9aae91ef/html5/thumbnails/11.jpg)
Diabetic Neuropathy
Current treatmentCareful blood sugar controlDrug treatment of symptoms
eg painkillers, metacloprimide, Viagra
DietFoot hygiene and maintenanceExercise
![Page 12: 3679.ppt](https://reader035.vdocuments.site/reader035/viewer/2022062802/563dbb99550346aa9aae91ef/html5/thumbnails/12.jpg)
Underlying Mechanisms
Agreement not yet reached on exact causal relationship between insulin imbalance and
nerve damage.
The relative importance and inter-relationship of the various mechanisms is the subject of
ongoing research and debate.
![Page 13: 3679.ppt](https://reader035.vdocuments.site/reader035/viewer/2022062802/563dbb99550346aa9aae91ef/html5/thumbnails/13.jpg)
Physical manifestations
Nerve fibres degenerateBlood vessels supplying the nerves are
‘grossly diseased’
Any theory needs to account for both
![Page 14: 3679.ppt](https://reader035.vdocuments.site/reader035/viewer/2022062802/563dbb99550346aa9aae91ef/html5/thumbnails/14.jpg)
Pathways of action
Polyol pathwayTriose phosphate effectsFailure of nerve growth & repair mechanismFatty acid metabolism
![Page 15: 3679.ppt](https://reader035.vdocuments.site/reader035/viewer/2022062802/563dbb99550346aa9aae91ef/html5/thumbnails/15.jpg)
Polyol Pathway
Polyol = Polyhydroxy alcoholsHigh blood glucose
Nerve cell and capillary membranes have insulin-independent glucose transport.
High intra-cellular glucose levelsConversion of glucose to sorbitol in nerve
cells by aldose reductase enzymeSorbitol cannot cross membranes and
therefore accumulates
![Page 16: 3679.ppt](https://reader035.vdocuments.site/reader035/viewer/2022062802/563dbb99550346aa9aae91ef/html5/thumbnails/16.jpg)
Polyol Pathway
Consequences of high sorbitol concentration:Osmotic damage to nerve cellsreduction in nerve myoinositol Inhibition of nitric oxide (NO) production
Aldose reductase competes for NADPHNO is vasodilator
Increased production of free radicalsSuperoxide, hydrogen peroxide, hydroxylFormed during mitochondrial respirationIncreased oxidative stress (proteins, lipids, DNA)
![Page 17: 3679.ppt](https://reader035.vdocuments.site/reader035/viewer/2022062802/563dbb99550346aa9aae91ef/html5/thumbnails/17.jpg)
Polyol Pathway
Treatment possibilitiesAldose reductase inhibitorsSupplemental myoinositolNitric oxide stimulation/sensitisationVasodilatorsAntioxidants
![Page 18: 3679.ppt](https://reader035.vdocuments.site/reader035/viewer/2022062802/563dbb99550346aa9aae91ef/html5/thumbnails/18.jpg)
Triose phosphates
High intracellular glucose leads increased production of triose phosphatesActivation of protein kinase C (PKC) via DAG
Damages capillaries (permeability, contractility)Damages nerve function
Non-enzymic reaction with proteins & DNAAdvanced Glycation End-products (AGEs)Damage to capillaries and nerve fibresSpecific cellular AGE receptorsProtein cross-linking
![Page 19: 3679.ppt](https://reader035.vdocuments.site/reader035/viewer/2022062802/563dbb99550346aa9aae91ef/html5/thumbnails/19.jpg)
Treatment possibilities
PKC inhibitorsRemove AGE precursors
α-Oxoaldehyde scavengers
Block AGE receptorsBlock protein cross linking
Aminoguanidine
![Page 20: 3679.ppt](https://reader035.vdocuments.site/reader035/viewer/2022062802/563dbb99550346aa9aae91ef/html5/thumbnails/20.jpg)
Nerve Growth and Repair
Reduced levels of :Nerve Growth Factor (NGF)Neurotrophin 3 (NT-3)
Supplementation does not influence nerve blood flow or motor conduction velocity in rats
![Page 21: 3679.ppt](https://reader035.vdocuments.site/reader035/viewer/2022062802/563dbb99550346aa9aae91ef/html5/thumbnails/21.jpg)
Fatty acid metabolism
Diet Liver Plasma Membranes
Linoleic Linoleic
GLA
DGLA
Arachidonic Arachidonic Arachidonic
DGLA DGLA
Type 1(&2?)
Type 1&2
![Page 22: 3679.ppt](https://reader035.vdocuments.site/reader035/viewer/2022062802/563dbb99550346aa9aae91ef/html5/thumbnails/22.jpg)
Fatty acid metabolism
Functions of DGLA and AA in nervesIncorporated into membranes
required for normal nerve structure, which is required for normal nerve conduction
Required for regulation of nerve conductionvia inositol/calcium cycle and PGE1
Required for microvascular systemDLMG - Prostaglandin E1
AA - Prostacyclin
![Page 23: 3679.ppt](https://reader035.vdocuments.site/reader035/viewer/2022062802/563dbb99550346aa9aae91ef/html5/thumbnails/23.jpg)
Fatty acid metabolism
Failure of incorporation may be because of:actual reduced incorporation; orexcessive peroxidation; orexcessive removal
Overcome conversion blockage by supplementing with GLA
Evening primrose oil contains 9% GLA
![Page 24: 3679.ppt](https://reader035.vdocuments.site/reader035/viewer/2022062802/563dbb99550346aa9aae91ef/html5/thumbnails/24.jpg)
GLA Animal Studies
All studies in streptozotocin rats show prevention and reversal of neuropathy
Acts primarily through increased nerve blood flow
Mainly through increased prostacyclin and hence nitric oxide
No effect on polyol pathway
![Page 25: 3679.ppt](https://reader035.vdocuments.site/reader035/viewer/2022062802/563dbb99550346aa9aae91ef/html5/thumbnails/25.jpg)
GLA Human Studies
12 x 500 mg capsules/day EPO3 randomised placebo-controlled studies
1) 22 patients in 1 centreAll parameters improved in GLA groupAll parameters deteriorated in placebo groupMany of differences statistically significant
2) 111 patients in 7 centres3) 293 patients in 10 centres
![Page 26: 3679.ppt](https://reader035.vdocuments.site/reader035/viewer/2022062802/563dbb99550346aa9aae91ef/html5/thumbnails/26.jpg)
GLA Human Studies
28 Parameters measured in studies 2&3:Conduction velocityAction potential amplitudesDetection of temperature changes (hot & cold)Sensory functionsMuscle strengthReflexes
![Page 27: 3679.ppt](https://reader035.vdocuments.site/reader035/viewer/2022062802/563dbb99550346aa9aae91ef/html5/thumbnails/27.jpg)
GLA Human StudiesCombined results (n=404)
20
3
2
3
P<0.001
P<0.01
P<0.05
NS
28 parameters - all improved relative to placebo
***
**
*
NS
![Page 28: 3679.ppt](https://reader035.vdocuments.site/reader035/viewer/2022062802/563dbb99550346aa9aae91ef/html5/thumbnails/28.jpg)
GLA Human Studies
Confirm animal studiesDemonstrate beneficial effectNo effect on glycosylated haemoglobinVery safe
26 events reported on active (n=202)34 events reported on placebo (n=202)mostly mild gastrointestinal upsetnone serious
![Page 29: 3679.ppt](https://reader035.vdocuments.site/reader035/viewer/2022062802/563dbb99550346aa9aae91ef/html5/thumbnails/29.jpg)
GLA + ARIs
GLA does not affect polyol pathwayComplimentary effect?Streptozotocin-treated ratsThreshold doses of EPO and 2 ARIsMeasure:
Nerve conduction velocityVascular conductance
Use two ARIs with different modes
![Page 30: 3679.ppt](https://reader035.vdocuments.site/reader035/viewer/2022062802/563dbb99550346aa9aae91ef/html5/thumbnails/30.jpg)
GLA + ARIsEffect on nerve conduction velocity
SZT
EPO ZDWAY
EPO+ZDEPO+WAY
-10
10
30
50
70
90
110
NORMAL
WAY = WAY121509 ZD = ZD5522
** * **
***
***%
![Page 31: 3679.ppt](https://reader035.vdocuments.site/reader035/viewer/2022062802/563dbb99550346aa9aae91ef/html5/thumbnails/31.jpg)
GLA + ARIsEffect on nerve vascular conductance
SZT
EPO ZD
-10
10
30
50
70
90
110
NORMAL
ZD = ZD5522
%EPO+ZD
* *
***
![Page 32: 3679.ppt](https://reader035.vdocuments.site/reader035/viewer/2022062802/563dbb99550346aa9aae91ef/html5/thumbnails/32.jpg)
GLA + ARIs
Combined effect is much greater than additive
Additive Observed
EPO required
ZD5522 required
0.8x
1.8x
13.3x
6.8x
Dose required to produce same effect as other component
![Page 33: 3679.ppt](https://reader035.vdocuments.site/reader035/viewer/2022062802/563dbb99550346aa9aae91ef/html5/thumbnails/33.jpg)
GLA + ARIs
No effect of EPO on polyol pathwayNo effect on glycosylated haemoglobin
Vitamin C as an alternative?Effective ARIPowerful antioxidant (protects GLA)May be deficient in diabeticsTransport into cells also controlled by insulin
![Page 34: 3679.ppt](https://reader035.vdocuments.site/reader035/viewer/2022062802/563dbb99550346aa9aae91ef/html5/thumbnails/34.jpg)
GLA + Vitamin C
Streptozotocin-treated ratsIncluded meglumine salt of ascorbyl-GLA
Novel compoundDelivers vit C and GLA to same siteGLA moiety makes vit C lipid soluble
![Page 35: 3679.ppt](https://reader035.vdocuments.site/reader035/viewer/2022062802/563dbb99550346aa9aae91ef/html5/thumbnails/35.jpg)
GLA + Vitamin CEffect on nerve conduction velocity
SZT
VitC
EPO
VitC+EPO
AscGLA
-10
10
30
50
70
90
110
NORMAL
*
***%
***
***
n=128
![Page 36: 3679.ppt](https://reader035.vdocuments.site/reader035/viewer/2022062802/563dbb99550346aa9aae91ef/html5/thumbnails/36.jpg)
GLA + Vitamin CEffect on nerve vascular conductance
SZTVitC
GLA
VitC+GLA
AscGLA
-10
10
30
50
70
90
110
130
NORMAL%
***
***
***
NS
n=128
![Page 37: 3679.ppt](https://reader035.vdocuments.site/reader035/viewer/2022062802/563dbb99550346aa9aae91ef/html5/thumbnails/37.jpg)
GLA + Lipoic acid
Lipoic acid is a naturally occurring free radical scavenger
‘metabolic antioxidant’Regenerates major antioxidants
vit C, glutathione, thioredoxone, ubiquinone
Protects NO synthesis
![Page 38: 3679.ppt](https://reader035.vdocuments.site/reader035/viewer/2022062802/563dbb99550346aa9aae91ef/html5/thumbnails/38.jpg)
GLA + Lipoic AcidEffect on nerve conduction velocity
SZT
LPAGLA
LpaGla
-10
10
30
50
70
90
110
NORMAL
%
n=128
**
*** ***
**
LPA+GLA
![Page 39: 3679.ppt](https://reader035.vdocuments.site/reader035/viewer/2022062802/563dbb99550346aa9aae91ef/html5/thumbnails/39.jpg)
GLA + Lipoic AcidEffect on nerve vascular conductance
SZT
LPA GLA
LPA+GLA
0
20
40
60
80
100
120
140
NORMAL%
NS
n=128
NS
*** ***
LpaGla
![Page 40: 3679.ppt](https://reader035.vdocuments.site/reader035/viewer/2022062802/563dbb99550346aa9aae91ef/html5/thumbnails/40.jpg)
Synergistic Effects
GLA acts via prostacyclinVitamin C and Lipoic Acid act via Nitric
OxideTogether their effect is much greater than
would be expected from additivityPotential treatment for neuropathy?
![Page 41: 3679.ppt](https://reader035.vdocuments.site/reader035/viewer/2022062802/563dbb99550346aa9aae91ef/html5/thumbnails/41.jpg)
Commercial Situation
EPO was rejected by regulatorsGLA therefore discredited in industryOriginal company foldedPatent protection running outMay not see products commercialised